ReviewOncoTargets and therapy2018
Functional miRNAs in breast cancer drug resistance.
Review in OncoTargets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnosis of hepatocellular carcinoma using liquid biopsy-based biomarkers: a systematic review and network meta-analysis.Frontiers in oncology · 2024Pooled it
- Programmable hairpin assembly circuit-cascaded DNAzyme amplification for ultrasensitive miRNA-146a detection via high-stable perovskite nanocomposite biosensor.Analytical and bioanalytical chemistry · 2026Article
- Defective biological networks associated with pseudogene-derived lncRNAs in cancer drug resistance: Promising prospects for their clinical targets in cancer therapy.Genes & diseases · 2026Review
- Integrative miRNOMe profiling reveals the miR-195-5p-CHEK1 axis and its impact on luminal breast cancer outcomes.Molecular oncology · 2025Article
- miRNAs as emerging predictors of tamoxifen resistance in breast cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Isoetin from Isoetaceae Exhibits Superior Pentatransferase Inhibition in Breast Cancer: Comparative Computational Profiling with FDA-Approved Tucatinib.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Targeting drug resistance in breast cancer: the potential of miRNA and nanotechnology-driven delivery systems.Nanoscale advances · 2024Review
- Interplay between Wnt signaling molecules and exosomal miRNAs in breast cancer (Review).Oncology reports · 2024Review
- Allicin Overcomes Doxorubicin Resistance of Breast Cancer Cells by Targeting the Nrf2 Pathway.Cell biochemistry and biophysics · 2024Article
- Effects of Eribulin on the RNA Content of Extracellular Vesicles Released by Metastatic Breast Cancer Cells.Cells · 2024Article
- miRNAs as biomarkers of therapeutic response to HER2-targeted treatment in breast cancer: A systematic review.Biochemistry and biophysics reports · 2024Review
- Restoring microRNA-34a overcomes acquired drug resistance and disease progression in human breast cancer cell lines via suppressing the ABCC1 gene.Breast cancer research and treatment · 2024Article
- Trials and Tribulations of MicroRNA Therapeutics.International journal of molecular sciences · 2024Review
- Potential biomarkers as a predictive factor of response to primary chemotherapy in breast cancer patients.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2024Article
- Circulating microRNAs as Potential Biomarkers in Pancreatic Cancer-Advances and Challenges.International journal of molecular sciences · 2023Review
- MiRNA-146a-A Key Player in Immunity and Diseases.International journal of molecular sciences · 2023Review
- Circulating miR-221/222 expression as microRNA biomarker predicting tamoxifen treatment outcome: a case-control study.Annals of medicine and surgery (2012) · 2023Article
- Review
- Exosomal transfer of miR-181b-5p confers senescence-mediated doxorubicin resistance via modulating BCLAF1 in breast cancer.British journal of cancer · 2023Article
- Resistance of breast cancer cells to paclitaxel is associated with low expressions of miRNA-186 and miRNA-7.Cancer drug resistance (Alhambra, Calif.) · 2023Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Owing to improved early surveillance and advanced therapy strategies, the current death rate due to breast cancer has decreased; nevertheless, drug resistance and relapse remain obstacles on the path to successful systematic treatment. Multiple mechanisms responsible for drug resistance have been elucidated, and miRNAs seem to play a major part in almost every aspect of cancer progression, including tumorigenesis, metastasis, and drug resistance. In recent years, exosomes have emerged as novel modes of intercellular signaling vehicles, initiating cell-cell communication through their fusion with target cell membranes, delivering functional molecules including miRNAs and proteins. This review particularly focuses on enumerating functional miRNAs involved in breast cancer drug resistance as well as their targets and related mechanisms. Subsequently, we discuss the prospects and challenges of miRNA function in drug resistance and highlight valuable approaches for the investigation of the role of exosomal miRNAs in breast cancer progression and drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.